Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S. D'Haens G, et al. Among authors: kobayashi t. Eur J Gastroenterol Hepatol. 2024 Apr 1;36(4):404-415. doi: 10.1097/MEG.0000000000002728. Epub 2024 Feb 21. Eur J Gastroenterol Hepatol. 2024. PMID: 38417060 Free PMC article.
Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome.
Toyonaga T, Kobayashi T, Nakano M, Saito E, Umeda S, Okabayashi S, Ozaki R, Hibi T. Toyonaga T, et al. Among authors: kobayashi t. PLoS One. 2017 Sep 21;12(9):e0185131. doi: 10.1371/journal.pone.0185131. eCollection 2017. PLoS One. 2017. PMID: 28934315 Free PMC article.
Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease.
Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T; ADJUST study group. Tanaka H, et al. Among authors: kobayashi t. J Gastroenterol Hepatol. 2018 May;33(5):1031-1038. doi: 10.1111/jgh.14034. Epub 2018 Mar 15. J Gastroenterol Hepatol. 2018. PMID: 29087616
Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S, Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T; INDIGO Study Group. Naganuma M, et al. Among authors: kobayashi t. Gastroenterology. 2018 Mar;154(4):935-947. doi: 10.1053/j.gastro.2017.11.024. Epub 2017 Nov 22. Gastroenterology. 2018. PMID: 29174928 Clinical Trial.
Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T; DIAMOND2 Study Group. Hisamatsu T, et al. J Gastroenterol. 2019 Oct;54(10):860-870. doi: 10.1007/s00535-019-01582-w. Epub 2019 Apr 30. J Gastroenterol. 2019. PMID: 31041545 Clinical Trial.
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. Sandborn WJ, et al. Among authors: kobayashi t. Gastroenterology. 2020 Feb;158(3):562-572.e12. doi: 10.1053/j.gastro.2019.08.027. Epub 2019 Aug 28. Gastroenterology. 2020. PMID: 31470005 Free article. Clinical Trial.
14,551 results
You have reached the last available page of results. Please see the User Guide for more information.